.png){kind=icon}
.png){kind=icon}
Return
Diagnostic value of delayed-phase 99mTc-HSA scintigraphy and treatment outcomes in connective tissue disease-associated protein-losing enteropathy
.png){kind=icon}
PRE
AI
X
B
H
Y
G
Z
H
X
N
D
DOI：10.1007/s10067-026-08350-1.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
To characterize the clinical spectrum, diagnostic value of delayed-phase 99mTc-HSA scintigraphy, and therapeutic outcomes in connective tissue disease-associated protein-losing enteropathy (CTD-PLE). A retrospective study evaluated patients undergoing 99mTc-HSA scintigraphy at the First Affiliated Hospital of Sun Yat-sen University (March 2021–October 2025). The diagnostic protocol included standard early-phase imaging (1 and 3 h), with conditional 6-h delayed imaging for negative or inconclusive initial scans. Among 77 patients who underwent 99mTc-HSA scintigraphy for suspected PLE, 31 (40.3%) had underlying CTDs, primarily Sjögren’s syndrome (n = 12) and systemic lupus erythematosus (n = 11). Severe hypoproteinemia with serous effusions predominated (93.5%), whereas gastrointestinal symptoms were infrequent (35.5%). Conventional endoscopic and cross-sectional imaging findings were largely nonspecific. Scintigraphy most frequently demonstrated tracer leakage in the jejunum and ileum. Delayed 6-h imaging identified additional sites of protein leakage in approximately half of the patients with negative or inconclusive early-phase findings. Following glucocorticoid-based immunosuppression (prednisone in 31, cyclophosphamide in 16, methotrexate in 6), albumin and complement levels improved significantly within 3 months. Complete remission was achieved in 14 patients, and partial remission in 5. Over a median 10-month follow-up (IQR 2–24), no relapses were documented among patients who achieved remission and remained under observation. In this cohort, delayed 6-h imaging revealed additional protein leakage sites in approximately half of the patients with negative or inconclusive early-phase scintigraphy, suggesting potential diagnostic value. Individualized immunosuppressive therapy targeting the underlying CTD was associated with favorable clinical outcomes. Further prospective studies are warranted to validate these findings.
Keywords:
Connective tissue diseases
Immunosuppression therapy
Protein-losing enteropathies
Radionuclide imaging
Journal
IF:
2.8
Papers:
1.1K
Citations:
1.3W
Organization
View more organizations